MX2024013138A - Anticuerpos específicos contra la proteína 7 relacionada con la angiopoyetina y usos de estos - Google Patents

Anticuerpos específicos contra la proteína 7 relacionada con la angiopoyetina y usos de estos

Info

Publication number
MX2024013138A
MX2024013138A MX2024013138A MX2024013138A MX2024013138A MX 2024013138 A MX2024013138 A MX 2024013138A MX 2024013138 A MX2024013138 A MX 2024013138A MX 2024013138 A MX2024013138 A MX 2024013138A MX 2024013138 A MX2024013138 A MX 2024013138A
Authority
MX
Mexico
Prior art keywords
angiopoietin
related protein
specific antibodies
present disclosure
optic nerve
Prior art date
Application number
MX2024013138A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Peterson
Original Assignee
Broadwing Bio Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broadwing Bio Llc filed Critical Broadwing Bio Llc
Publication of MX2024013138A publication Critical patent/MX2024013138A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2024013138A 2022-04-29 2024-10-24 Anticuerpos específicos contra la proteína 7 relacionada con la angiopoyetina y usos de estos MX2024013138A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263336747P 2022-04-29 2022-04-29
PCT/US2023/020354 WO2023212294A1 (en) 2022-04-29 2023-04-28 Angiopoietin-related protein 7-specific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2024013138A true MX2024013138A (es) 2025-02-10

Family

ID=86558903

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013138A MX2024013138A (es) 2022-04-29 2024-10-24 Anticuerpos específicos contra la proteína 7 relacionada con la angiopoyetina y usos de estos

Country Status (13)

Country Link
US (1) US20250296996A1 (cg-RX-API-DMAC7.html)
EP (1) EP4514470A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025517111A (cg-RX-API-DMAC7.html)
KR (1) KR20250021399A (cg-RX-API-DMAC7.html)
CN (1) CN119630698A (cg-RX-API-DMAC7.html)
AU (1) AU2023259251A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250430A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003281A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024016093A2 (cg-RX-API-DMAC7.html)
IL (1) IL316603A (cg-RX-API-DMAC7.html)
MX (1) MX2024013138A (cg-RX-API-DMAC7.html)
PE (1) PE20250560A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023212294A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240043520A1 (en) * 2022-08-03 2024-02-08 Fred Hutchinson Cancer Center Targeting of peri-necrotic tumor cells

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
FR2756297B1 (fr) 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
WO1999006562A1 (en) 1997-07-31 1999-02-11 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
WO2001023001A2 (en) 1999-09-29 2001-04-05 The Trustees Of The University Of Pennsylvania Rapid peg-modification
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
PL2657248T3 (pl) 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
WO2011051276A1 (en) * 2009-10-26 2011-05-05 Externautics S.P.A. Colon and rectal tumor markers and methods of use thereof
CN104302408B (zh) 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
US20160346359A1 (en) 2015-05-01 2016-12-01 Spark Therapeutics, Inc. Adeno-associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease
WO2017173043A1 (en) 2016-03-30 2017-10-05 Spark Therapeutics, Inc. Cell line for recombinant protein and/or viral vector production
WO2019126222A1 (en) 2017-12-18 2019-06-27 Spark Therapeutics, Inc. Adeno-associated virus (aav) vector lipid nanoparticle compositions and methods of use
US20210363192A1 (en) 2018-04-27 2021-11-25 Spark Therapeutics, Inc. Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same
WO2019217483A1 (en) 2018-05-07 2019-11-14 Spark Therapeutics, Inc. Plasmid free aav vector producing cell lines
CA3119349A1 (en) 2018-11-16 2020-05-22 Spark Therapeutics, Inc. In vitro assay for detecting enhancers and inhibitors of adeno associated virus (aav) vector transduction and/or detecting or quantitating anti-aav binding antibodies

Also Published As

Publication number Publication date
JP2025517111A (ja) 2025-06-03
CO2024016093A2 (es) 2025-02-13
AU2023259251A1 (en) 2024-11-14
IL316603A (en) 2024-12-01
EP4514470A1 (en) 2025-03-05
CN119630698A (zh) 2025-03-14
KR20250021399A (ko) 2025-02-12
US20250296996A1 (en) 2025-09-25
CL2024003281A1 (es) 2025-05-02
CA3250430A1 (en) 2023-11-02
WO2023212294A1 (en) 2023-11-02
PE20250560A1 (es) 2025-02-24

Similar Documents

Publication Publication Date Title
Xue et al. Genipin-crosslinked donor sclera for posterior scleral contraction/reinforcement to fight progressive myopia
Phan et al. Topical fibronectin in the treatment of persistent corneal epithelial defects and trophic ulcers
Vestergaard et al. Long-term outcomes of photorefractive keratectomy for low to high myopia: 13 to 19 years of follow-up
CN111032070A (zh) 用于治疗眼病的脂联素拟肽
Green Mussel adhesive protein
CN102026648A (zh) 用于治疗干眼和/或角膜结膜损伤的药物组合物
CL2024003281A1 (es) Anticuerpos específicos contra la proteína 7 relacionada con la angiopoyetina y usos de estos
WO2021220061A3 (en) Heterodimer compositions and methods for the treatment of ocular disorders
Zhang et al. Neural stem cell-based intraocular administration of pigment epithelium-derived factor promotes retinal ganglion cell survival and axon regeneration after optic nerve crush injury in rat: an experimental study
MX2024003012A (es) Nuevo polipeptido.
MY205498A (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
CN106943590B (zh) 一种包含ngf的用于治疗角膜上皮损伤的药物组合物
HK1252301A2 (zh) 一种含有重组人溶菌酶的新型人工泪液
EP1037622A4 (en) TAURIN DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISORDERS
AU2020299145A8 (en) Compositions and methods for treating eye diseases
Halabis Analysis of the corneal endothelium in keratoconus
Ellakwa et al. Corneal wavefront guided versus aberration free transepithelial photorefractive keratectomy in myopic patients with high pre-existing corneal higher order aberrations
MX2022009136A (es) Composicion farmaceutica oftalmica y uso de la misma.
RU2716429C1 (ru) Способ лечения рецидивирующей эрозии роговицы различного генеза
EA200100655A1 (ru) Способ изготовления состава местных бета-блокаторов улучшенного действия
Firdous et al. PRESERVATIVE FREE SODIUM HYALURONATE 0.15% IN DRY EYE DISEASE PATIENTS TREATED WITH PROSTAGLANDIN ANALOGUES FOR PRIMARY OPEN-ANGLE GLAUCOMA IN KASHMIR: A PROSPECTIVE STUDY
EP4299588A3 (en) Treatment methods for eye disorders
RU2301651C1 (ru) Способ коррекции сферической аберрации, возникающей во время проведения эксимерлазерной абляции роговицы в коррекции миопии
Ucgun et al. Effect of Bevacizumab on Vitreous Tumor Necrosis Factor Alpha and Matrix Metalloproteinases in Eyes with Choroidal Neovascular Membranes
US20260083730A1 (en) Methods of treating eye disorders